uniQure N.V. (QURE) is a publicly traded Healthcare sector company. As of May 21, 2026, QURE trades at $24.60 with a market cap of $1.57B and a P/E ratio of -7.01. QURE moved -0.45% today. Year to date, QURE is +8.71%; over the trailing twelve months it is +60.68%. Its 52-week range spans $4.45 to $71.50. Analyst consensus is buy with an average price target of $38.80. Rallies surfaces QURE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
uniQure to File Q3 2026 AMT-130 UK MAA After 75% Huntington’s Slowing: uniQure expects to submit a UK MAA for AMT-130 in Q3 2026 following an MHRA pre-submission meeting that reviewed its three-year Phase I/II results showing a 75% disease progression slowdown (p=0.003). A Type B FDA meeting in Q2 2026 will discuss Phase III design and four-year data.
| Metric | Value |
|---|---|
| Price | $24.60 |
| Market Cap | $1.57B |
| P/E Ratio | -7.01 |
| EPS | $-3.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $71.50 |
| 52-Week Low | $4.45 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $18.09M |
| Net Income | $-208.87M |
| Gross Margin | 90.56% |
12 analysts cover QURE: 0 strong buy, 8 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $38.80.